Implandata Ophthalmic Products GmbH, based in Hannover, Germany, is at the forefront of digital health innovation, specifically targeting the underserved area of glaucoma care with cutting-edge technologies and products.

The CE-approved eyemate® system is a revolutionary solution that blends advanced medical technology with digital health innovations. This system significantly enhances therapy delivery and disease management for glaucoma patients, offering a comprehensive and efficient approach to their care.

The eyemate® system features an implantable micro sensor that measures intraocular pressure, which is then read by a hand-held device. This data is wirelessly transmitted to a secure database, allowing doctors to make timely adjustments to treatments. Additionally, a smartphone app provides patients with critical disease information, treatment progress updates, and medication reminders, fostering a proactive approach to health management.

At Jameel Health, we are proud to partner with Implandata Ophthalmic Products GmbH on this transformative journey in eye care. This collaboration underscores our commitment to advancing healthcare globally, making sophisticated medical solutions accessible to all.

Implandata’s eyemate® system signifies a major advancement in managing glaucoma, providing personalized therapy guidance and empowering patients to take control of their health. Through our partnership, Jameel Health is dedicated to distributing this innovative technology widely, particularly across the Global South, ensuring that even the most underserved communities have access to advanced healthcare solutions.